Drug Type T-lymphocyte cell therapy |
Synonyms Human MHC non-restricted cytotoxic T-cell line - Galileo Research, ABIO-0501, TALL 104 + [1] |
Target- |
Action stimulants |
Mechanism Cell death stimulants, Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Epithelial Carcinoma | Phase 2 | Italy | 25 Apr 2015 | |
Leukemia | Phase 2 | United States | 03 Mar 2015 | |
Lymphoma | Phase 2 | United States | 03 Mar 2015 | |
Chronic phase chronic myeloid leukemia | Phase 2 | United States | 01 Dec 2006 | |
Peritoneal Neoplasms | Phase 2 | Italy | - |
Phase 2 | 6 | vdoeeartva = bormqzpkpf xjnlozkcde (ljltqikgja, qpxxyvdxgj - ndgwaxbnge) View more | - | 17 Mar 2020 | |||
Phase 2 | 3 | Imatinib Mesylate (IM)+TALL-104 cells | pnrpblvsgl = vhwhajcxdn vjynqflihu (wqzqonoqih, fkthnyuucs - yurdowsdbm) View more | - | 30 Jun 2014 |